FDA rejects Mesoblast's cell therapy for bone marrow transplant complications

The U.S. Food and Drug Administration had rejected Mesoblast's cell therapy for children under 12 years of age for treating a type of complication that occurs after a stem cell or bone marrow transplant, the company said on Thursday.